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Antimicrobial peptides (AMPs) are promising antimicrobials, however, the potential of
bacterial resistance is a major concern. Here we systematically study the evolution of
resistance to 14 chemically diverse AMPs and 12 antibiotics in Escherichia coli. Our work
indicates that evolution of resistance against certain AMPs, such as tachyplesin II and
cecropin P1, is limited. Resistance level provided by point mutations and gene amplification is
very low and antibiotic-resistant bacteria display no cross-resistance to these AMPs.
Moreover, genomic fragments derived from a wide range of soil bacteria confer no detectable
resistance against these AMPs when introduced into native host bacteria on plasmids. We
have found that simple physicochemical features dictate bacterial propensity to evolve
resistance against AMPs. Our work could serve as a promising source for the development of
new AMP-based therapeutics less prone to resistance, a feature necessary to avoid any
possible interference with our innate immune system.
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Antimicrobial peptides (AMPs) are short, structurallydiverse peptides with a broad spectrum of antibacterialactivities. Although there is considerable diversity in the
amino acid content, length, and structure among peptides, typi-
cally, they are positively charged and amphipathic1. AMPs are
present in all classes of life, and are inherent part of the defense
mechanisms against microbial pathogens. In vertebrates, many
provide protection against pathogens and also have modulatory
roles in the innate immune system2,3. AMPs frequently target the
bacterial membrane by forming pores on it. This process is
initiated by the interaction between the positively charged AMP
and the negatively charged components of bacterial cell wall,
including lipopolysaccharides (LPS) and phospholipids4. AMPs
can also interfere with central cellular processes, such as DNA
and protein syntheses, protein folding, and cell wall synthesis5,6.
Given their broad spectrum of activity, much effort has been
made to find potential novel antibacterial drug candidates among
AMPs, although skeptics have raised issues concerning low
peptide stability, costly production, and pleiotropic biological
effects7,8.
Evolution of resistance against AMPs was initially thought to
be less likely due to the rapid bactericidal effects and multiple
potential bacterial targets of these compounds1,9. However, small-
scale studies indicate several major mechanisms of resistance,
including the bacterial release of molecules that neutralize the
exogenous peptide, enzymatic decay by bacterial proteases, and
the modification of the outer bacterial membrane to prevent
AMP binding or uptake10–14. Also, there are reasonable concerns
that the therapeutic use of certain AMPs could drive a rapid
evolution of resistance to host-defense peptides with immune-
related functions in the human body15,16. This is a pressing issue,
as several synthetic AMPs are currently tested in clinical trials
(the majority of them are proposed for topical use)2,3.
However, the scope of AMPs is broad. There are thousands of
registered AMPs derived from a wide range of organisms, with
distinctive physicochemical, structural and functional
characteristics17,18. Therefore, major variations may exist in the
probability or resistance of different AMPs. There is an increasing
demand for a better understanding of AMP-specific resistance
mechanisms, as it would greatly influence the capacity to design
more efficient AMP-based drug candidates2,3,13.
A better understanding of AMP-specific resistance demands
studying multiple AMPs in a range of bacterial species. Moreover,
bacteria can acquire resistance through diverse genetic mechan-
isms, including point mutations, amplification of genomic seg-
ments, and horizontal transfer of resistance genes. Therefore,
these mechanisms should be studied systematically in the
laboratory. Finally, it is of central importance to compare the rate
of resistance evolution against AMPs and clinically employed
antibiotics.
Here we systematically characterize bacterial potential to
acquire resistance against a set of chemically diverse AMPs
(Supplementary Table 1). For this purpose, we combine labora-
tory evolution, systematic gene overexpression studies and
functional metagenomics. We integrate the results of these
complementary tests to get a global overview of AMP resistance
evolution. We reveal a limited probability of resistance develop-
ment against certain AMPs. Such AMPs could serve as a pro-
mising source for the development of resistance-free, AMP-based
drug candidates.
Results
Laboratory evolution of resistance to AMPs. Our first goal was
to study resistance evolution against a set of AMPs and anti-
biotics. We have followed established protocols with minor
modifications to evolve bacterial populations under controlled
laboratory conditions19,20. The applied protocol aims to max-
imize the level of drug resistance in the evolving populations
achieved during a fixed time period. We have initiated a
laboratory evolution experiment, starting with a single clone of
Escherichia coli K-12 BW25113 (abbreviated as E. coli K-12
BW25113). Parallel evolving populations were exposed to
increasing concentrations of one of 14 AMPs (Supplementary
Table 1). Peptides were chosen based on the following criteria:
diverse sources (synthetic/natural), different putative mechanisms
of action, structural diversity, and clinical relevance. Another set
of populations were exposed to one of 12 clinically relevant
antibiotics (Supplementary Table 2), using the same protocol.
Accordingly, we have propagated 10 independent populations in
the presence of each AMP or antibiotic for ∼120 generations. We
isolated a single, representative clone from each population,
resulting in 140 AMP-adapted lines and 120 antibiotic-adapted
lines. Throughout the paper, we compare the level of resistance in
the evolved lines to the corresponding wild-type strain by mea-
suring changes in the drugs’ minimum inhibitory
concentrations (MIC).
In agreement with prior studies, the evolution of resistance
against small-molecule antibiotics was a rapid process21–23. The
median antibiotic resistance levels were ~90 times higher
compared to the wild-type strain (Fig. 1a and Supplementary
Data 1). Resistance levels induced by AMP treatments were
significantly lower and more heterogeneous on average than the
resistance levels evoked by antibiotic treatments (Fig. 1a). Like
most antibiotics studied here, certain AMPs are also prone to
resistance. For instance, polymyxin B (PXB)—an AMP used as a
last-resort drug in the treatment of multidrug-resistant Gram-
negative bacterial infections24—is a notable example. During the
course of our laboratory evolution, bacterial susceptibility to PXB
decreased, reaching resistance levels of over 3000-fold higher than
that of the wild-type strain (Fig. 1a, Supplementary Data 1). In
agreement with other laboratory studies, we have also isolated
resistant mutants from populations exposed to pexiganan (PEX),
protamine (PROA), and PR-39 stresses25–27.
However, there was a low probability of resistance develop-
ment against some other AMPs. In particular, the average
increment in resistance level was less than threefold in
populations exposed to cecropin P1 (CP1), indolicidin (IND),
peptide glycine-leucine amide (PGLA) and pleurocidin (PLEU)
stresses (Fig. 1b). Strikingly, we have failed to detect any
resistance in the evolved lines exposed to tachyplesin II (TPII)
and R8 (Fig. 1a, Supplementary Data 1). However, bacterial lines
with an elevated mutation rate (mutators) are known to display
an exceptionally rapid evolution of antibiotic resistance28.
Therefore, we have tested whether resistance against TPII would
emerge in such mutator populations, but none of the 10
laboratory evolved mutator E. coli K-12 mutD5 populations
displayed resistance to TPII (Fig. 1a, Supplementary Data 1).
Next, we have also studied laboratory evolution under TPII and
PXB stresses in a range of pathogenic bacteria to see whether the
limited AMP resistance observed in E.coli K-12 BW25113 holds
in other bacterial strains and species. The tested pathogens
initially sensitive to the AMPs and the antibiotics included
Escherichia coli (ATCC® 25922™) (abbreviated as E. coli ATCC
25922), Salmonella enterica subsp. enterica serovar Typhimurium
LT2 (abbreviated as S. enterica LT2), Klebsiella pneumoniae
subsp. pneumoniae (Schroeter) Trevisan (ATCC® 10031™)
(abbreviated as K. pneumoniae ATCC 10031) and Acinetobacter
baumannii Bouvet and Grimont (ATCC® 17978™) (abbreviated as
A. baumannii ATCC 17978). In agreement with the results seen
with E. coli K-12 BW25113, a high level of PXB-resistance has
emerged in all pathogens studied: certain lines have displayed an
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increment of resistance level as high as 20,000 times compared to
the corresponding wild-type strain (Fig. 1b, Supplementary
Data 1). By sharp contrast, resistance to TPII has remained at
very low levels in all species (Fig. 1b, Supplementary Data 1).
Further studies should explore potential species-specific differ-
ences in resistance development.
Fitness costs of resistance. Prior studies have demonstrated that
antibiotic resistance frequently incurs a moderate fitness cost in
the absence of drug, analyzed by measuring growth rates in
laboratory conditions29. Such fitness costs seem to influence the
spread of antibiotic-resistant bacteria in clinical settings30.
However, fitness data on AMP-adapted lines is far more
limited31.
In this analysis, we focused on 60 antibiotic-adapted, 38 AMP-
adapted lines, all of which displayed at least twofold increment in
resistance level to the drug they had been exposed to during the
course of laboratory evolution. We estimated fitness by measuring
growth of these strains and the corresponding wild-type in
antibiotic-free medium (“Methods”). In total, 96.7% of the
antibiotic-resistant lines showed significantly reduced growth
compared to the wild-type strain, while this figure is 92.1% in the
case of AMP-adapted lines (Fig. 1c, Supplementary Data 2). We
conclude that the frequency of AMP (N= 38) and antibiotic (N
= 60) resistant strains with fitness cost are comparable to each
other (P= 0.37, Fisher’s two-sided exact test). As might be
expected13, fitness costs varied substantially across antibiotics and
AMPs (Fig. 1b). Intriguingly, however, the fitness cost of AMP-
adapted lines (N= 38) was significantly lower than that of
antibiotic-adapted lines (N= 60) (P < 2.2e-16, two-sided
Mann–Whitney U test). This pattern is unlikely to reflect
differences in the level of resistance between AMP and antibiotic
strains, respectively. There is only a weak, marginally significant
negative correlation between the level of resistance and fitness
AMPs
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Fig. 1 MIC and relative fitness of adapted lines after the laboratory evolution. a Relative resistance level in laboratory evolved E. coli K-12 BW2511 lines
exposed to one of each 14 AMPs (blue) or 12 antibiotics (red), respectively (at least 9 parallel-evolved lines per drug). Altogether, lines exposed to AMPs
(N= 138) developed significantly lower resistance, than lines exposed to antibiotics (N= 120) (P < 0.0001, one-sided permutation test). The resistance
levels reached were more heterogeneous across AMP treatments (N= 14) than across antibiotic treatments (N= 12) (P= 0.03478 F-test). Each data
point represents the MIC fold change of one of each parallel-evolved line. The mutD5 mutator strain exposed to TPII is marked by an asterisk (*). b Relative
resistance level after laboratory evolution in clinical isolates under TPII or PXB stresses, respectively. Evolved lines exposed to TPII reached significantly
lower resistance level than lines exposed to PXB (*** indicate the significant difference at least P-value= 1.65 × 10–4, two-sided Mann–Whitney test, N= 10
each group). Each data point represents the MIC fold change of one of each parallel-evolved line. c Relative fitness of 60 antibiotic-resistant and 38 AMP-
resistant lines displaying at least twofold increments in resistance level to the drug indicated. Fitness was measured as the area under the growth curve in
an antibacterial agent-free medium and was normalized to that of the wild-type (gray color). Throughout Fig. 1, boxplots show the median, first and third
quartiles, with whiskers showing the 5th and 95th percentile. For AMP and antibiotic abbreviations, see Supplementary Tables 1–2. Data in this figure are
representative of at least two biological replicates. Source data are provided as a Source Data file
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cost (Supplementary Fig. 1, Spearman’s rho=−0.24, P= 0.016
(N= 98)), and this correlation becomes non-significant after
controlling for drug type (P= 0.6 and P= 0.39 for antibiotics (N
= 60) and AMPs (N= 38) respectively, Spearman’s correlation).
Together, these results indicate that the lack of resistance against
certain AMPs during laboratory evolution cannot be explained by
differences in fitness costs.
Physicochemical features of AMPs with limited resistance.
Next, we have investigated how amino acid physicochemical
properties influence the rate of AMPs resistance evolution. To
this end, we have calculated the fraction of charged, polar and
hydrophobic amino acids for each AMP (Supplementary Data 3),
and have correlated those features with the average increment in
resistance level achieved during laboratory evolution (Fig. 1a).
The analysis has revealed that the AMPs less prone to resistance
tend to contain fewer polar and positively charged amino acids,
and display increased hydropathicity (Fig. 2).
No cross-resistance to AMPs with limited resistance. Next, we
have explored whether laboratory evolved AMP resistance pro-
vide any cross-resistance to AMPs which appear to be less prone
to resistance. For this purpose, we have isolated 38 independently
evolved lines, all of which have displayed resistance to the AMP
they had been exposed to in the laboratory (at least four lines per
AMP, see Supplementary Data 1). We have measured the changes
in susceptibilities of these strains to the AMPs (PLEU, PGLA, R8,
IND, TPII, and CP1) towards which resistance evolution was
limited, as well as to the human peptide LL37. LL37 is a
cathelicidin-derived AMP present throughout the human body
with critical defensive roles32. Cross-resistance was defined as a
minimum of twofold increase in resistance level.
Three main findings have emerged from the analysis. First,
13.4% of all possible combinations of the AMPs and the evolved
lines have displayed cross-resistance (Fig. 3, Supplementary
Data 4). Second, only 5 out of the 33 non-LL37 adapted lines
have shown cross-resistance to the human peptide LL37.
Moreover, 4 out of these 5 adapted lines had been exposed to
CAP18 during the course of laboratory evolution. As CAP18
belongs to the cathelicidin family32, chemical relatedness may
drive cross-resistance to LL37. Third, and most significantly, none
of the 38 AMP-resistant lines displayed cross-resistance to R8,
TPII, and CP1 (Fig. 3, Supplementary Data 4). These results
further confirm that resistance mutations against these specific
AMPs are particularly rare.
Molecular mechanisms underlying AMP resistance. To identify
mutational events underlying AMP resistance, the 38 AMP-
adapted lines characterized above were subjected to whole-
genome sequencing using Illumina platform. We have imple-
mented an established computational pipeline to identify point
mutations, small insertions and deletions that had accumulated
during the course of laboratory evolution21,22. Altogether, 197
independent mutational events have been identified (Supple-
mentary Data 5). On average, we have detected 1.45 deletions,
0.61 insertions and 2.21 single nucleotide polymorphisms (SNPs)
per a single clone. To statistically test whether the ratio of non-
synonymous to synonymous SNPs was higher than expected
based on a neutral model of evolution, we employed an estab-
lished method33, that is especially well-suited for experimental
evolution studies with limited number of observed mutations34.
Briefly, we took all different point mutations observed in protein
coding regions and calculated the probability that 94% or more
substitutions would result in a non-synonymous substitution if it
occurred in a random coding position. The excess of non-
synonymous substitution observed in the evolved genomes was
significant (p= 0.000004, one-sided permutation test34).
Thirty percent of the affected genes were mutated repeatedly
(i.e., at least three times), and 94% of these genes have acquired
mutations in lines adapted to at least two different AMPs
(Figs. 4a, b, Supplementary Data 5). Several repeatedly mutated
proteins and molecular pathways had been previously linked to
AMP resistance in laboratory or clinical settings (Supplementary
Data 6). The most relevant proteins were members of the waa-
operon and the Mla-pathway involved in LPS and phospholipid
trafficking, respectively, and the BasS-BasR two-component
sensor system. This two-component system regulates both the
LPS pathway and phospholipid trafficking35.
Next, we have investigated whether mutations in the most
relevant genes provide resistance to those AMPs which are less
prone to resistance (e.g., TPII, R8 and CP1). Thus, a selected
human beta-defensin-3 (HBD3) resistant line carrying a single
mutation in BasS (basS L194R), mlaD (mlaD a342del) and WaaY
(waaY M1†) was chosen for further analysis. The observed
mutations were inserted individually into the E. coli K-12
BW25113. The mutations conferred resistance to human
HBD3, but no resistance to R8, CP1 or TPII (Supplementary
Data 4). We conclude that commonly observed AMP resistance
mutations provide no resistance to these AMPs.
AMP resistance via reduced net negative surface charge. LPS
are major components of bacterial outer membrane, responsible
for regulating permeability and contributing to negative surface
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Fig. 2 Resistance level correlate with AMPs’ physicochemical features. Each datapoint shows the average MIC-fold change in laboratory evolved E. coli K-12
BW2511 lines exposed to one of each 14 AMPs. a Fraction of polar amino acids and relative resistance level (Spearman’s rho= 0.58; p= 0.03, N= 14).
b Fraction of positively charged and relative resistance level (Spearman’s rho= 0.62; p= 0.02, N= 14). c AMP hydropathicity and relative resistance level
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charge36. Consequently, LPS composition has a major impact on
bactericidal efficiency of cationic AMPs. As proteins related to
several mutated genes regulate outer membrane or LPS compo-
sition in particular (Supplementary Data 5), we hypothesized that
bacterial populations developed AMP resistance partly via the
modifications of LPS structure, ultimately leading to a reduced
net negative surface charge of the outer membrane. To investigate
this hypothesis, we have carried out surface charge measurements
on 16 representative AMP-adapted lines (two lines per AMP).
The analysis has revealed that 13 of the 16 AMP-adapted lines
tested displayed significantly reduced negative surface charge of
the outer bacterial membrane compared to the wild-type strain
(Fig. 5). These lines were frequently found to carry mutations in
the BasR-BasS two-component sensor system. Indeed, the
representative mutation in BasS, when introduced into E. coli K-
12 BW25113, caused a major reduction in net negative surface
charge, potentially explaining its impact on resistance (Fig. 5).
However, it is probable that many other mutated genes contribute
to the observed changes in negative surface charge of the outer
membrane.
The impact of gene amplification on resistance. Bacterial gene
amplification generates extensive genetic variation that can pro-
vide drug resistance37,38. As gene amplification events tend to be
genetically unstable and reduce bacterial fitness, they are transient
in nature39. Using the ASKA library, which comprises each E. coli
ORF cloned into an expression vector40, we have conducted a
global survey to evaluate whether artificially amplified genes
provide resistance to any of the 14 AMPs and 11 antibiotics
tested. As chloramphenicol (CHL) was used as a selection marker
for the ASKA plasmid40, this antibiotic was not tested in this
screen. E. coli K-12 BW25113 cells were transformed with the
pooled plasmids of the ASKA library, and the genetically mixed
populations were exposed to increasing levels of AMP or anti-
biotic stresses, respectively. In all cases, the employed AMP or
antibiotic dosages were above the MIC of the wild type. For each
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drug, we identified the MIC provided in the pooled ASKA plas-
mid library, and compared it to the MIC of the wild-type strain
carrying the empty ASKA plasmid.
When transformed into E. coli K-12 BW25113, the pooled
ASKA library provides a 2- to 64-fold increment in antibiotic
resistance level, suggesting that gene amplification can have an
important contribution to resistance (Fig. 6a, Supplementary
Table 3). Consistent with a prior study41, trimethoprim (TRM)
resistance level was found to get increased by 32-fold as a result of
gene overexpression. By sharp contrast, the same library induced
no detectable increment in resistance level to 8 out of the 14
AMPs tested, including R8, IND, TPII and CP1. Moreover, the
artificial gene amplification of native genes was found to provide
only a maximum 1.6-fold change in resistance level to the
remaining 6 AMPs (Fig. 6a).
Functional metagenomics of a soil library. As AMPs are pro-
duced by a diverse set of organisms to promote immune defenses,
nutrient acquisition or elimination of competitors from the
environment, they are found in a many environments42, includ-
ing mammalian tissues, soil43–45 and aquatic environments. For
example, Bacillus polymyxa inhabits soil, plant roots, and marine
sediments44, and produces clinically relevant polymyxins. Soil is
also an ancient reservoir of antibiotic resistance genes and it has
been shown that antibiotic resistance genes can be exchanged
between soil dwelling and pathogenic bacteria46. For all these
reasons, we consider soil as a relevant source environment to
study the mobilization potential of AMP-resistance genes.
Briefly, metagenomic DNA was cut, and fragments between
1.5–5 kb were shotgun cloned into a plasmid to express the
genetic information in E. coli K-12 BW25113 (for details see
“Methods”). About 1.8 million members of the constructed
library, corresponding to a total coverage of 3.6 Gb (the size of
~900 bacterial genomes), were then selected on solid culture
medium in the presence of one AMP or antibiotic. We have
focused on four AMP candidates found to be less prone to
resistance induced by genomic mutations (R8, IND, TPII and
CP1, Fig. 1a), and four, clinically relevant small-molecule
antibiotics with diverse modes of action (TRM, TOB, CHL, and
CPR). Resistant clones were isolated, and the number of unique
DNA fragments conferring resistance (i.e., resistance contigs) was
determined by sequencing. In agreement with prior studies46,47,
multiple genetically independent resistant clones were found to
emerge against all tested antibiotics (Fig. 6b, Supplementary
Data 7). By contrast, no resistant clone was observed against the
tested AMPs (Fig. 6b). These results suggest that mobile
resistance genes against these AMPs are relatively rare in the
soil.
Antibacterial activity and toxicity analysis of TPII and CP1. As
described above, we have identified AMPs that appear to be less
prone to mutation- and plasmid-mediated resistance develop-
ment alike. Two of these AMPs, TPII and CP1, could be pro-
mising candidates for future therapeutic considerations. Both
CP1 and TPII exhibit broad-spectrum activity against Gram-
negative bacteria (Supplementary Table 4). A hemolysis assay
indicates that both TPII and CP1 exhibit only a minimal hae-
molytic effect (<10% hemolysis) even at concentrations two
orders of magnitude higher than their MICs against bacteria
commonly associated with resistance (i.e., ESKAPE pathogens,
see Supplementary Table 5). We calculated the activity/toxicity
index (ATI)48, the ratio of the concentration causing 10%
hemolysis (minimum haemolytic concentration, MHC) and the
median of MICs (MM). It was found that ATI is relatively high
for CP1 and TPII against all bacteria tested (Supplementary
Table 6). Future in vivo studies should be performed to confirm
these findings.
rpo genes (RNA polymerase)
a b
topA (DNA topoisomerase 1)
skp (OM protein chaperone)
ptsP (nitrogen metabolism)
proQ (RNA chaperone)
pgsA (pl metabolism)
0
1
2
3
4
5
7
Number of
mutations
Mutation profile similarity
[Jaccard index]
0.0
0.2
0.4
0.6
BAC5_3
BAC5_5
BAC5_7
BAC5_10
PR39_1
PR39_2
PR39_5
PR39_7
PR39_10
PROA_2
PROA_3
PROA_7
PROA_8
PROA_9
CAP18_2
CAP18_5
CAP18_6
CAP18_8
CAP18_10
HBD3_3
HBD3_6
HBD3_8
HBD3_10
LL37_1
LL37_3
LL37_6
LL37_7
LL37_10
PEX_1
PEX_4
PEX_5
PEX_7
PXB_2
PXB_5
PXB_6
PXB_8
PXB_10
B
A
C
5_
3
B
A
C
5_
5
B
A
C
5_
7
B
A
C
5_
10
P
R
39
_1
P
R
39
_2
P
R
39
_5
P
R
39
_7
P
R
39
_1
0
P
R
O
A
_2
P
R
O
A
_3
P
R
O
A
_7
P
R
O
A
_8
P
R
O
A
_9
C
A
P
18
_2
C
A
P
18
_5
C
A
P
18
_6
C
A
P
18
_8
C
A
P
18
_1
0
H
B
D
3_
3
H
B
D
3_
6
H
B
D
3_
8
H
B
D
3_
10
LL
37
_1
LL
37
_3
LL
37
_8
LL
37
_7
LL
37
_1
0
P
E
X
_1
P
E
X
_4
P
E
X
_5
P
E
X
_6
P
E
X
_7
P
X
B
_2
P
X
B
_5
P
X
B
_6
P
X
B
_8
PEX_6
ECA synthesis
pitA (phosphate transporter)
aceE (pyruvate dehydrogenase)
asmA (putative OM assembly protein)
pagP (PL and lipid A modifications)
macAB macrolide ABC exporter
yeb genes (PL translocation)
mla pathway (OM asymmetry maintainance)
Ipx genes (Lipid A biosynthesis)
Ipt machinery (LPS export)
waa pathway (LPS core biosynthesis)
BasSR two-component system
CpxA-CpxR two-component system
Cytochrome d
yej genes
Δ yhi-ars genes
Δ sbmA-related
Δ CP4–6 prophage
B
A
C
5
P
R
39
P
R
O
A
H
B
D
3
LL
37
C
A
P
18
P
E
X
P
X
B
Fig. 4 Mutational profiles of 38 AMP-resistant lines. a The figure shows cellular complexes and pathways mutated independently in multiple lines as a
function of AMPs used during laboratory evolution. The color code indicates the number of individual mutations affecting a given cellular subsystem in
lines evolved to a given AMP. OM outer membrane, PL phospholipid, LPS lipopolysaccharide, Δ gene deletion. b Heatmap shows mutation profile similarity
of AMP-resistant lines. Mutation profile similarity between each pair of AMP-resistant lines was estimated by the Jaccard’s coefficient between their set of
mutated genes. Large deletions were counted as one gene. AMP-resistant lines are named after the AMP it has been exposed to during the evolutionary
experiment, and the serial number of the corresponding population. For AMP abbreviations, see Supplementary Table 1
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12364-6
6 NATURE COMMUNICATIONS |         (2019) 10:4538 | https://doi.org/10.1038/s41467-019-12364-6 | www.nature.com/naturecommunications
Discussion
AMPs are promising novel antimicrobial agents2, but evolution of
resistance against AMPs is a major health concern14,16. This issue
is all the more important as knowledge on AMP resistance could
direct the design of novel AMPs for clinical applications49. Pre-
dicting the risk of resistance formation against new antibiotic
agents is a notoriously difficult task, as a complex interplay of
several factors shapes the rise and evolutionary fate of drug
resistant bacteria in clinical settings30. The most important fac-
tors include (a) the frequency by which resistance arises by
endogenous mutations or horizontal gene transfer, (b) the level of
resistance conferred by combinations of resistance mechanisms,
(c) the potential fitness costs of resistance, and (d) the extent of
cross-resistance between drugs. In this work, we investigated
these issues with a range of clinically relevant antibiotics and
functionally/chemically diverse AMPs. Six main patterns have
emerged from our study.
First, parallel evolving populations were exposed to increasing
concentrations of one of 14 AMPs and 12 clinically relevant
antibiotics, respectively. All the antibiotics studied, as well as
certain AMPs were found to be prone to resistance (Fig. 1a). For
example, susceptibility to PXB substantially decreased during the
course of our laboratory evolution, reaching a resistance level of
over 3000-fold higher compared to the wild-type strain. This is
important, as PXB and related AMPs are used as last-resort
therapeutics in the treatment of multidrug-resistant Gram-nega-
tive bacterial infections50. We have also identified repeatedly
mutated proteins, putatively linked to AMP resistance, including
proteins involved in LPS modification and transport (waa-
operon), phospholipid trafficking (Mla-pathway), and a two-
component sensor system (BasR-BasS). These proteins most
likely act via the modification of bacterial outer membrane
components19, ultimately leading to a reduced net negative sur-
face charge of the outer membrane (Fig. 5). For other molecular
mechanisms associated to AMP resistance, see Supplementary
Data 5.
Second, laboratory evolution has revealed that there was a very
low probability of resistance against some other AMPs, including
CP1, IND, TPII, and R8 (Fig. 1a). The rate by which resistance
mutations arise depends on the mutational supply rate (i.e., the
product of genomic mutation rate and population size). Intrigu-
ingly, even E. coli populations with elevated genomic mutation
rate failed to develop resistance against TPII. Importantly, AMP-
adapted lines were found to display no cross-resistance to R8,
TPII, and CP1, indicating that resistance mutations against these
AMPs are particularly rare (Fig. 3). We wish to emphasize that
the level of resistance in bacterial populations was measured by
growth inhibition assays. Therefore, it is an open issue whether
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Fig. 5 Surface charge measurement. Relative surface charge was measured as the relative change in the binding of the positively charged FITC-PLL
compared to the wild-type (see Methods). The table on the right side shows whether the adapted line carries a mutation in the waa or mla pathway genes
or in the BasSR two-component system. AMP-resistant lines are named after the AMP it has been exposed to during the evolutionary experiment, and the
serial number of the corresponding population. Each data point represents the relative fluorescence unit of one of 9 biological replicate. Boxplots show the
median, first and third quartiles, with whiskers showing the 5th and 95th percentile. Significant differences compared to the wild type are marked with gray
asterisks (*P < 0.05, **P < 0.01, ***P < 0.001, two-sided Dunnett’s test, N= 9 each group). Source data are provided as a Source Data file
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mutations that shape persistence during lethal drug exposure
without any major effect on resistance are wide-spread.
Third, the fitness cost is another potentially relevant parameter
shaping the long-term fate of drug resistant bacteria. We found that
96.7% of the antibiotic-resistant and 92.1% of the AMP-adapted
lines display reduced growth compared to the wild type. In agree-
ment with prior studies, the fitness costs associated with AMP
resistance was moderate compared to the fitness cost of antibiotic-
resistant lines (Fig. 1c). This suggests that fitness cost alone is
unlikely to explain why some AMPs are not particularly prone to
resistance.
Fourth, AMPs less prone to resistance during adaptive labora-
tory evolution tend to display increased hydropathicity and con-
tain fewer polar and positively charged amino acids (Fig. 2). The
exact cellular mechanisms behind this phenomenon remain to be
elucidated in future research. However, we note that these phy-
sicochemical properties influence the capacity of several AMPs to
adopt an amphipathic conformation upon binding to the nega-
tively charged bacterial outer membrane51. As AMP resistance is
often achieved via altering the surface charge of the outer mem-
brane, we speculate that AMPs with relatively few positively
charged amino acids might be less prone to resistance by altered
membrane surface charge. This hypothesis should be tested in
more detail and with a larger number of AMPs in the future.
Fifth, we have conducted a global analysis to explore whether
artificially amplified genes provide resistance to individual AMPs
or antibiotics. This is relevant, as bacterial gene amplification
generates extensive genetic variation that can provide antibiotic
resistance37,38. For each antibiotic and AMP, we identified the
MIC provided by the pooled gene overexpression plasmid library,
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and compared it to the MIC of the wild-type strain carrying the
empty ASKA plasmid. We have demonstrated that gene ampli-
fication can have an important contribution to antibiotic resis-
tance. By contrast, the same library has resulted in no increment
in resistance level against 8 of the AMPs tested. These AMPs
include R8, TPII, and CP1 (Fig. 6a, Supplementary Table 3). It is
important to note that we cannot exclude the possibility that
overexpression of genes or combinations thereof enhance bac-
terial growth rate under sublethal concentrations of AMP stress.
This issue, along with the in-depth exploration of the intrinsic
AMP resistome will be studied in future chemical genomic
analyses52.
Sixth, we have investigated whether AMP resistance genes are
available for genetic exchange across bacterial species present in the
soil. The soil bacterial community is a rich source of mobile anti-
biotic resistance genes53, and several soil bacterial species display
AMP resistance54,55. Using standard tools of functional metage-
nomics, we have failed to find DNA segments that would provide
resistance against R8, IND, TPII, and CP1 when transferred into E.
coli (Fig. 6b). These results are consistent with a prior work showing
that resistance genes in the human gut microbiome originating
from phylogenetically distant bacteria have only a limited potential
to confer AMP resistance in E. coli, an intrinsically susceptible
species56. One possible reason for these patterns could be that AMP
resistance may an intrinsic bacterial property, potentially influenced
by a large number of interacting genes. If so, horizontal gene
transfer of short genomic fragments would not provide resistance in
the recipient bacterial species.
In sum, our analysis indicates that the frequency by which
AMP resistance arises is relatively low and even if it occurs, such
genetic changes provide only relatively low levels of resistance.
Why is it so? We hypothesize two complementary mechanisms
that should be studied in future works. First, evolution of AMP
resistance may be hindered by the limited availability of resistance
mutations. Multi-targeting drugs in which a single compound
inhibits more than one target are generally considered as a pro-
mising therapeutic strategy against the rise of resistance57. It
remains to be elucidated whether AMPs less prone to resistance
identified in our study target multiple cellular subsystems. Sec-
ond, the AMP dose range under which resistance can evolve may
be limited. Indeed, AMPs significantly differ from antibiotics in
their pharmacodynamics properties. In particular, their bacter-
icidal activity is generally characterized by a sharp increase within
a narrow dose range, which is in contrast with the pharmaco-
dynamics of many antibiotics58. An important limitation of our
work is that we studied evolution and fitness costs of AMP and
antibiotic resistance in laboratory conditions only. Future works
should elucidate the diversity of AMP resistance mechanisms in
more realistic clinical settings.
Finally, our work identifies that TPII and CP1 are promising
candidates for future therapeutic considerations, for the following
reasons. They are active against a wide range of bacterial pathogens
with a relatively high activity/toxicity (ATI) index. We note how-
ever, that existing data on the toxicity of the tachyplesin anti-
microbial family are controversial48,59–61. Promisingly, and in
agreement with our results, a previous work showed that CP1 has
negligible toxicity or haemolytic activity62. Furthermore, evolution
of resistance against these AMPs is improbable in E. coli. We
propose that these AMPs could serve as a promising base for the
development of peptide based drug candidates with limited
resistance.
Methods
Strains. Unless otherwise indicated, we used E. coli K-12 BW25113 in all high-
throughput experiments. To investigate the impact of mutation rate on evolution of
AMP resistance, we initiated laboratory evolution with a mutator strain E. coli
mutD5 that carries mutations in the dnaQ gene (L73W and A164V). This strain
exhibits a 102–103-fold increase in mutation rate63. Evolution of resistance against
TPII and PXB was also studied in four clinically relevant pathogenic strains,
including Escherichia coli (ATCC® 25922™) (abbreviated as E. coli ATCC 25922),
Salmonella enterica subsp. enterica serovar Typhimurium LT2 (abbreviated as S.
enterica LT2), Klebsiella pneumoniae subsp. pneumoniae (Schroeter) Trevisan
(ATCC® 10031™) (abbreviated as K. pneumoniae ATCC 10031) and Acinetobacter
baumannii Bouvet and Grimont (ATCC® 17978™) (abbreviated as A. baumannii
ATCC 17978). We further tested the spectrum of activity of the most promising
compounds on a set of 20 ESKAPE pathogens and other clinically relevant strains:
E. coli ATCC 25922, Escherichia coli (ATCC® 35218™), Escherichia coli NCTC
13351, Escherichia coli (ATCC® BAA-2469™), Escherichia coli (ATCC® BAA2340™),
Shigella sonnei HNCMB 25021, Shigella flexneri HNCMB 20018, Enterobacter
cloacae subsp. cloacae (ATCC® 13047™), S. enterica LT2, Salmonella enteritidis
HNCMB 10092, K. pneumoniae ATCC 10031, Klebsiella pneumoniae NCTC
13440, Klebsiella pneumoniae subsp. pneumoniae (ATCC® 700603™), A. baumannii
ATCC 17978, Pseudomonas aeruginosa (ATCC® 27853™), Enterococcus faecium
(ATCC® 700221™), Streptococcus pyogenes ATCC 19615, Staphylococcus aureus
subsp. aureus (ATCC® 25923™), Staphylococcus aureus subsp. aureus (ATCC®
29213™), and Staphylococcus aureus subsp. aureus (ATCC® 43300™).
Antibacterial agents. Fourteen cationic AMPs were investigated in this study:
PROA, Pleuricidin (PLEU), Bactenecin 5 (BAC5), Human beta-defensin-3
(HBD3), cathelicidin antimicrobial peptide LL-37, IND, rabbit CAP18, PEX,
peptide glycine-leucine-amide (PGLA), PR39 (a proline-arginine-rich peptide with
39 residues), R8, Cecropin P1 (CP1), Polymyxin B (PXB) and TPII (Supplementary
Table 1). All AMPs were synthesized by ProteoGenix except PXB and PROA which
were purchased from Sigma-Aldrich. AMP solutions were prepared in sterile water
and stored at −80 °C until usage.
Twelve antibiotics were applied in this study: Tetracycline (TET), Doxycycline
(DOX), CHL, Erythromycin (ERY), TRM, Ampicillin (APC), Cefoxitin (FOX),
Nalidixic acid (NAL), Ciprofloxacin (CPR), Nitrofurantoin (NIT), Tobramycin
(TOB), and Kanamycin (KAN) (Supplementary Table 2). All antibiotics were
ordered from Sigma-Aldrich except for ERY (obtained from AMBRESCO) and
DOX (purchased from AppliChem). Upon preparation, each antibiotic stock
solution was filter-sterilized and kept at −20 °C until usage.
Medium. Unless otherwise indicated, Minimal Salt (MS) medium was used in all
experiments, including the laboratory evolution experiments. In line with previous,
methodologically relevant laboratory evolution studies, the physical conditions
(including the medium) were the same during the course of laboratory evolution
and all forthcoming assays on the resulting resistant lines (e.g. MIC measure-
ments). We previously optimized this medium for studying AMPs (1 g L−1
(NH4)2SO4, 3 g L−1 KH2PO4 and 7 g L−1 K2HPO4 supplemented with 0.1 mM
MgSO4, 0.54 µg mL−1 FeCl3, 1 µg mL−1 thiamine hydrochloride, 0.2% Casamino
acids and 0.2% glucose)19. This medium is highly controlled and provides a
reproducible environment for experimental evolution experiments. All components
were obtained from Sigma-Aldrich.
Laboratory-evolution experiment. The evolutionary protocol was designed to
avoid population extinction and to ensure that populations with the highest level of
resistance were propagated further. Starting with a subinhibitory drug concentra-
tion (Supplementary Data 8), resulting in ~50% growth inhibition, 10 parallel
populations per drug were allowed to grow in Minimal Salts medium for 72 h and
300 r.p.m. E. coli K-12 BW25113 and E. coli mutD5 populations were incubated at
30 °C, while E. coli ATCC 25922, S. enterica LT2, K. pneumonia ATCC 10031, and
A. baumannii ATCC 17978 were incubated at 37 °C. After each incubation period,
20 μl of the 370 μl culture was transferred to four new independent wells containing
fresh medium and increasing dosages of the antimicrobial agent (0.5×, 1×, 1.5×,
and 2.5× the concentration of the previous step). Prior to each transfer, cell growth
was monitored by measuring the optical density at 600 nm (OD600 value, Biotek
Synergy 2 microplate reader). Only populations with the highest drug concentra-
tion (and reaching OD600 > 0.2) were selected for further evolution. A chess-board
layout was used on the plate to monitor potential cross-contamination events. The
evolution experiment was continued for 20 transfers, resulting in a total of 138
AMP (two lines were omitted because of limited growing) and 120 antibiotic-
adapted E. coli K-12 BW25113 lines. E. coli ATCC 25922, S. enterica LT2, K.
pneumonia ATCC 10031, and A. baumannii ATCC 17978 were adapted to PXB
and TPII, resulting in 10 populations per peptide for each species. E. coli mutD5
was adapted to TPII, also in 10 parallel evolving populations. Dose-response curves
of E. coli K-12 BW25113 strain against AMPs and antibiotics are provided in
Supplementary Fig. 2A and 2B, respectively.
Determination of MIC. MICs were determined using a standard serial broth
dilution technique64. Briefly, 11-step serial dilutions were prepared in 96-well
microtiter plates with three replicates per strain and antimicrobial compound. Each
experiment was repeated at least twice. 5 × 105 cells/mL were inoculated into each
well, and the plates were incubated at 30 °C in case of E. coli K-12 BW25113, and
its antibiotic and AMP-adapted lines, or 37 °C in case of the other bacterial species.
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Plates were shaken at 300 r.p.m. during incubation for 24 and 18 h, respectively.
Cell growth was monitored by measuring the optical density (OD600 value, Biotek
Synergy 2 microplate reader was used for this purpose). MIC was defined as
complete growth inhibition (i.e., OD600 < 0.05). Relative MIC was calculated as
follows: MICrelative=MICevolved/MICcontrol. Neither pre-incubation (72 h) nor the
exact timing of MIC measurement had any major effect on the MIC of AMPs
(Supplementary Table 7).
High-throughput fitness measurements. Bacterial cell growth was assayed by
continuously monitoring the optical density (OD600) of liquid cultures using 384-
well microtiter plates containing MS medium, the same medium used during the
laboratory evolution. Fitness was measured for a total of 60 antibiotic-adapted and
the 38 AMP-adapted E. coli K-12 BW25113 lines (at least four lines per antibiotic
or AMP). All measurements were performed twice (six technical replicates per
experiment). Starter cultures were inoculated into 96-well plates containing MS
medium and incubated for 20 h at 30 °C for E. coli K-12 BW25113 and its evolved
lines. After this growth period, the OD600 of each culture was read and the starting
cell number set to a final of 50,000 cells per well to a final volume of 60 µl. A total of
384-well plates were inoculated combining four different 96-well starter plates
together: one plate having the unevolved wild-type control as a reference strain in
all wells in order to estimate possible variation in growth within-plate measure-
ment causing biases to the reading, and three plates containing the different set of
antibiotic or AMP-adapted lines. Cell growth was monitored by measuring the
optical density at 600 nm every 5 min (OD600 value, Biotek Synergy 2 microplate
reader was used for this purpose). The integral data was calculated by the Biotek
Gen5 Data Analysis Software between 1 and 24 h in case of E. coli K-12 BW25113
adapted lines. Because of possible influence of temperature equilibration in the first
hour of measurement, this time period was excluded from the analysis.
Screening of a gene overexpression library. The ASKA library (a complete set of
E. coli K-12 ORF archive) includes every E. coli ORF cloned into an expression
vector (pCA24N)65. Prior to screening, the ASKA plasmid collection was pooled
and transformed into E. coli K-12 BW25113 strain66. The plasmid pool was created
by pooling an equal aliquot of cells, each carrying different members of the ASKA
library, followed by plasmid miniprep. Next, the plasmid pool was electroporated
into E. coli K-12 BW25113 competent cells. The electroporation resulted in a
number of transformants that covered the full library at least 100 times. For the
MICs measurements 500 000 cells were inoculated in each well which represents
~100 times coverage of each library member. To determine the changes in the MIC
caused by the overexpression of a specific gene, a 96-well microtiter plate was
prepared that contained a 12 step concentration gradient of the corresponding
AMP or antibiotic in MS medium supplemented with 10 µg mL−1 CHL and 500
µM isopropyl-ß-D-thiogalactopyranoside (IPTG). Prior to the measurements the
cell population containing the pooled overexpression library or the control strain
containing the empty vector were grown in three replicates in LB medium sup-
plemented with 20 µg/mL CHL. As the culture reached high density (i.e.,
OD600 > 0.8), expression of the plasmid was induced by 50 µM IPTG for 1 h.
Following induction, 5 × 105 bacterial cells were inoculated in three replicates into
each well of the 96-well plate and incubated for 16–18 h at 37 °C. Following
incubation the MIC values were determined by measuring optical densities in a
plate reader (Biotek Synergy).
Functional metagenomic screen. In order to characterize the horizontally
transferable resistome of soil bacteria against four AMPs and four antibiotics, we
identified small genomic fragments (1.5–5 kb) that decrease drug susceptibility
against the tested AMPs or antibiotics when expressed from a multicopy plasmid
with an inducible promoter. For the construction of the metagenomic library, an
agricultural soil sample was obtained from Kaposvár, Hungary. Soil community
DNA was isolated using Quick-DNA™ Fecal/Soil Microbe Miniprep Kit (Zymo
Research) according to the manufacturer’s instructions. Then, we followed the
steps of the library construction protocol described by Kintses et al.56. The average
insert size was ~2 kb. The size of the library (3.6 Gb) was estimated by multiplying
the average insert size by the number of total colony forming units (CFU).
Functional selections for resistance genes were carried out on solid plates
containing one of the four AMPs (R8, TPII, CP1, and IND) or one of the four
antibiotics (CPR, CHL, TRM, TOB) serving as controls. Instead of the plating assay
that is commonly used in the field67, we applied a modified gradient plate assay68,
where bacteria are exposed to a concentration gradient of the antimicrobial instead
of a single concentration. We followed the steps of the functional metagenomic
selection protocol described by Kintses et al56. Briefly, 2 × 108 cells were plated out
from the thawed stocks of E. coli K-12 BW25113 bearing the metagenomic plasmid
library. In this way, each member of the metagenomic library was represented
about 10–100 times on each plate. We found this necessary for a good
reproducibility of our experiments. Subsequently, plates were incubated at 30 °C for
24 h. For each functional selection, a control plate was prepared where the same
number of E. coli K-12 BW25113 was plated out. These cells contained the pZErO-
2 plasmid with a random metagenomic DNA insert that has no effect on AMP or
antibiotic resistance. This control plate showed the MIC of the AMP/antibiotic
without the effect of a resistance plasmid. The empty plasmid was not applicable as
a control because in the absence of a DNA insert the CcdB toxic protein is
expressed from the plasmid. In order to isolate the resistant clones from the library
plates, sporadic colonies were identified above the MIC level (defined using the
control plate) by visual inspection. These clones were collected by scraping them
into 2 ml of LB broth and stored subsequently at −80 °C. Plasmid pools from the
scraped resistant clones were PCR amplified for subsequent Illumina sequencing.
To this aim, first, the plasmid pools were isolated from each metagenomic selection
using InnuPREP Plasmid Mini Kit (Analytic Jena). Then, these plasmid pools
served as templates for subsequent PCR amplification of the inserts. These PCR
reactions and the subsequent Illumina sample preparation and sequencing were
performed as described by Kintses et al.56.
To assemble the Illumina sequencing reads into longer DNA contigs, we have
applied a previously established workflow with modifications46. We validated and
optimized our workflow on a mock sample containing 5 previously sequenced
DNA contigs that originate from one of our metagenomic selections. Reads from
the MiSeq 2 × 250 bp PE sequencing were pre-processed in Genomics Workbench
Tool version 9.0 (CLC Bio) including the following steps: reads were first quality
trimmed with an error threshold of 0.05. Then overlapping PE pairs where
subsequently merged. Merged and unmerged reads were mapped to pZErO-2
reference plasmid, keeping only those reads that did not match the plasmid
sequence. Pre-processed data was then randomly down-sampled to 0.5, 1, 2, 4, 8,
16, 32, 64 and 100% with two replicates generated at each sampling point. MIRA
4.0.2 (http://MIRA-assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html)
was then used to perform de novo sequence assembly separately on each replicate.
De novo contigs from MIRA were screened for the presence and proper orientation
of the PCR oligonucleotides keeping only complete assembly products. Complete
contigs were further filtered based on their average coverage values keeping only
the top 20% best-covered ones within each sampling point. Contigs from all
sampling points were then pooled. Redundant contigs displaying at least 90%
sequence identity to each other over at least 80% of their lengths were clustered
using NCBI blastp, keeping only one representative sequence per cluster. The
remaining contigs were filtered once more based on their average coverage values
until only those Illumina contigs remained in the mock sample which have a
corresponding counterpart in the reference Sanger sequences with 100% sequence
identity. This criterion was satisfied when contigs with the lowest sequence
coverage, forming a distinct peak in the density plot of the coverage distributions,
were removed. The optimized workflow was applied for the assembly of the DNA
contigs coming from the metagenomic selections. To functionally analyse the ORFs
on the assembled contigs from the metagenomic selections, ORFs were predicted
and annotated using the Prokka suite (version 1.1169) with bacterial prediction
settings and an e-value threshold of 10−5 (ref. 56).
Whole-genome sequencing. To identify potential mechanisms conferring resis-
tance to AMPs, we selected those peptides to which at least 2 out of the 10 adapted
lines reached a minimum of fivefold increase in resistance (MIC). A total of 38
AMP-adapted lines (at least 4 lines per peptide, see Supplementary Data 1) were
chosen for whole-genome sequencing. E. coli K-12 BW25113 genomic DNA was
prepared with Sigma GenElute™ Bacterial Genomic DNA Kit and quantified using
Qubit dsDNA BR assay in a Qubit 2.0 fluorometer (Invitrogen). Two hundred
nanograms of genomic DNA was fragmented in a Covaris M220 focused-
ultrasonicator (peak power: 55W, duty factor: 20%, 200 cycles/burst, duration: 45
s) using Covaris AFA screw cap fiber microTUBEs. Fragment size distribution was
analyzed by capillary gel electrophoresis using Agilent High Sensitivity DNA kit in
a Bioanalyzer 2100 instrument (Agilent) then indexed sequencing libraries were
prepared using TruSeq Nano DNA LT kit (Illumina) following the manufacturer’s
protocol. This, in short, includes end repair of DNA fragments, fragment size
selection, ligation of indexed adapters and library enrichment with limited-cycle
PCR. Sequencing libraries were validated (library sizes determined) using Agilent
High Sensitivity DNA kit in a Bioanalyzer 2100 instrument then quantitated using
qPCR based NEBNext Library Quant Kit for Illumina (New England Biolabs) with
a Piko-Real Real-Time PCR System (Thermo Fisher Scientific) and diluted to 4 nM
concentration. Groups of 12 indexed libraries were pooled, denatured with 0.1 N
NaOH and after dilution loaded in a MiSeq Reagent kit V2–500 (Illumina) at 8 pM
concentration. 2 × 250 bp pair-end sequencing was performed with an Illumina
MiSeq sequencer, primary sequence analysis was done on BaseSpace cloud com-
puting environment with GenerateFASTQ 2.20.2 workflow. Paired end sequencing
data were exported in FASTQ file format. The reads were trimmed using Trim
Galore (Babraham Bioinformatics) and cutadapt70 to remove adapters and bases
where the PHRED quality value was <20. Trimmed sequences were removed if they
became shorter than 150 bases. FASTQC program (https://www.bioinformatics.
babraham.ac.uk/projects/fastqc/) was used to evaluate the qualities of original and
trimmed reads. The Breseq program was used with default parameters for all
samples. The gdtools was used for annotating the effects of mutations and com-
paring multiple samples. The genbank formatted reference genome BW25113.gb
was used as a reference genome in the analysis.
pORTMAGE-based insertion of resistance-associated mutations. pORT-
MAGE71 method was used to introduce three putative AMP resistance mutations
into the wild-type genetic background (E. coli K-12 BW25113). The mutations
include basS L194R, mlaD a342del and waaY M1†, and were identified in one of
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the human beta-defensin 3 (HBD3) adapted lines. Briefly, individual mutations
were constructed via synthetic ssDNA-mediated recombineering using the
pORTMAGE3 vector. The 90 nucleotide long ssDNA oligos were designed using
the MODEST tool72, and had complementary sequences to the replicating lagging
strand with a minimized secondary structure ( ≥−12 kcal mol−1). Oligonucleotides
were prepared using standard desalting by Integrated DNA Technologies (Coral-
ville, IA, USA). Recombineering was performed in the electrocompetent E. coli K-
12 BW25113 cells carrying pORTMAGE3 (Addgene plasmid ID: 72678). pORT-
MAGE3 was induced at 42 °C for 15 min to allow for efficient mutation-
incorporation while avoiding off-target mutagenesis71. Forty microliters of induced
electrocompetent cells were transformed with 1 µl of the respective 100 µM
mutation-carrying oligo. Cells were recovered in 5 mL Terrific-Broth (TB) media
(24 g yeast extract, 12 g tryptone, 9.4 g K2HPO4, and 2 g KH2PO4 per 1 L of water)
after electroporation and incubated at 30 °C for 60 min, after which 5 mL
Lysogeny-Broth-Lennox (LBL) media (10 g tryptone, 5 g yeast extract, 5 g sodium
chloride per 1 L water) was added. After this, cells were incubated at 30 °C over-
night. Appropriate dilutions of the cultures were then plated onto LBL agar plates
to form individual colonies and incubated at 30 °C overnight. Individual colonies
were screened using allele-specific PCR to identify ones carrying the desired
modifications. An allele-specific primer was designed and tested using wild-type
colonies employing a gradient PCR protocol using a Bio-Rad CFX96 Touch
thermocycler. The PCR annealing temperature for colony screening was then set at
a temperature 1 °C higher than the temperature where the last visible fragment
could be detected using the wild-type colony after gradient PCR. Candidate
colonies were subsequently verified using Sanger capillary-sequencing. Finally, the
pORTMAGE3 plasmid was cured from sequence-verified colonies by growing the
cells once overnight at 42 °C in antibiotic-free LBL media.
For a list of oligos and their sequences used for the mutation construction, see
Supplementary Data 9.
Surface charge measurement. To investigate changes in bacterial cell surface
charge, we performed a fluorescein isothiocyanate-labeled poly-L-lysine (FITC-
PLL) (Sigma) binding assay. FITC-PLL is a polycationic molecule that is widely
used to study the interaction between cationic AMPs and charged lipid bilayer
membranes73. In brief, cells were grown overnight in MS medium and then washed
twice with 1× phosphate-buffered saline (PBS) buffer. The cells were suspended in
the PBS buffer to a final OD600 of 0.1. The suspension was incubated with 6.5 µg/
mL FITC-PLL for 10 min and centrifuged at 5500 r.p.m. for 5 min. The amount of
FITC-PLL in the supernatant remaining after bacterial exposure (or no exposure in
case of the control) was determined fluorometrically (excitation at 500 nm and
emission at 530 nm). The quantity of FITC-PLL molecules bound to the bacterial
surface was calculated from the difference between the amount of FITC-PLL in the
control (no exposure) and the amount of unbound FITC-PLL (bacterial exposure).
The lower the amount of bound poly-L-lysine, the less negatively charged the cell
surface is.
Hemolysis assay. Human red blood cells (hemoglobin concentration (Hb)
150–160 g L−1) were collected from apparently healthy patients in EDTA tubes.
600 µL of EDTA-blood were washed in TBS buffer (10 mM TRIS, 150 mM NaCl)
and centrifuged at 1500 × g for 1 min until the supernatant became colorless. The
final pellet was diluted to 5 mL with TBS buffer. Hundred microliters of this cell
suspension was pipetted into sterile Eppendorf tubes together with twofold serial
dilutions of each compound to a final volume of 200 μl. Final concentrations
ranged between 2500 µg mL−1–9.75 µg mL−1. Following incubation for one hour at
37 °C, samples were centrifuged at 1500 g for 1 min to precipitate the red blood
cells. All supernatants were transferred to sterile 96-well plates for the measure-
ment of their direct optical density (OD) at 565 nm wavelength (Multiskan FC
microplate reader, Thermo Scientific). Melittin (Bachem) at concentration of 50 µg.
mL−1 and TBS were used as positive (100% hemolysis) and negative (no hemo-
lysis) controls, respectively. Haemolytic effect of each peptide at each concentration
was calculated as follows: Hemolysis effect= (Compound OD565nm − TBS
OD565nm) × 100/(Melitin OD565nm − TBS OD565nm).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that the main data supporting the findings of this study are available
within the article and its Supplementary Information files. Dose-response curves of
AMP-adapted lines are available from the corresponding author upon request. The
source data underlying Figs. 1a–c, 2a–c, 5, 6a–b and Supplementary Figs. 1 and 2a–b are
provided as a Source Data file. The whole-genome sequencing data can be accessed from
the NCBI GeneBank with access number: PRJNA555839 and the functional
metagenomics sequencing data can be accessed from MN256796-MN256836.
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